ES2409404T3 - Compuestos heterocíclicos de fenoximetilo - Google Patents

Compuestos heterocíclicos de fenoximetilo Download PDF

Info

Publication number
ES2409404T3
ES2409404T3 ES09796217T ES09796217T ES2409404T3 ES 2409404 T3 ES2409404 T3 ES 2409404T3 ES 09796217 T ES09796217 T ES 09796217T ES 09796217 T ES09796217 T ES 09796217T ES 2409404 T3 ES2409404 T3 ES 2409404T3
Authority
ES
Spain
Prior art keywords
formula
alkyl
optionally substituted
ring
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09796217T
Other languages
English (en)
Inventor
Gideon Shapiro
Amy Ripka
Richard Chesworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forum Pharmaceuticals Inc
Original Assignee
EnVivo Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnVivo Phamaceuticals Inc filed Critical EnVivo Phamaceuticals Inc
Application granted granted Critical
Publication of ES2409404T3 publication Critical patent/ES2409404T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de Fórmula (I) **Fórmula** o una de sus sales farmacéuticamente aceptables, en donde: HET es un anillo heterocíclico que tiene la fórmula A29 o A31 en donde el radical más a la izquierda está conectado al grupo X en la Fórmula (I); **Fórmula** X es arilo sustituido opcionalmente o heteroarilo sustituido opcionalmente, en donde los sustituyentes seseleccionan del grupo que consiste en alquilo C1-C4, cicloalquilo C3-C6, cicloalquil(C3-C6)oxi, alcoxi C1-C4, CF3,carboxi, alcoxialquilo, cicloalquilalcoxi C1-C4, amino, alquilamino, dialquilamino, amido, alquilamido, dialquilamido, tioalquilo, halógeno, ciano, alquilsulfonilo y nitro; Z es imidazo[1,2-a]piridin-2-ilo, imidazo[1,2-b]piridazin-2-ilo o imidazo[1,2-b]piridazin-6-ilo, cada uno de loscuales puede estar sustituido opcionalmente, en donde los sustituyentes se seleccionan del grupo que consisteen alquilo C1-C4, cicloalquilo C3-C6, cicloalcoxi C3-C6, alcoxi C1-C4, CF3, carboxi, alcoxialquilo, cicloalquilalcoxiC1-C4, amino, alquilamino, dialquilamino, amido, alquilamido, dialquilamido, tioalquilo, halógeno, ciano,alquilsulfonilo y nitro; y cada R2 es independientemente alquilo C1-C4 sustituido opcionalmente con flúor, o dos grupos R2 tomados juntocon el carbono al que están anclados forman un anillo de cicloalquilo de 3 miembros; y en donde: - alquilo indica un hidrocarburo C1-C8 alifático saturado o insaturado lineal o ramificado que puede estarsustituido opcionalmente con hasta 3 átomos de flúor y, si se especifica, sustituido con otros grupos; - arilo es un grupo fenilo o naftilo; - heteroarilo es un tetrazol, 1,2,3,4-oxatriazol, 1,2,3,5-oxatriazol, un sistema anular aromático mono o bicíclico, oun sistema anular heterobicíclico con un anillo aromático que tiene de 5 a 10 átomos anulares seleccionadosindependientemente entre C, N, O y S, siempre que no más de 3 átomos anulares en cualquier anillo sencillosean distintos de C; y - cicloalquilo es un hidrocarburo no aromático cíclico C3-C7 que puede contener un solo enlace doble y estásustituido opcionalmente e independientemente con hasta tres grupos seleccionados entre alquilo, alcoxi,hidroxilo y oxo.
ES09796217T 2009-05-07 2009-12-18 Compuestos heterocíclicos de fenoximetilo Active ES2409404T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17641309P 2009-05-07 2009-05-07
US176413P 2009-05-07
PCT/US2009/068644 WO2010128995A1 (en) 2009-05-07 2009-12-18 Phenoxymethyl heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2409404T3 true ES2409404T3 (es) 2013-06-26

Family

ID=41549054

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13150322.9T Active ES2554788T3 (es) 2009-05-07 2009-12-18 Compuestos Heterocíclicos de Fenoximetilo
ES09796217T Active ES2409404T3 (es) 2009-05-07 2009-12-18 Compuestos heterocíclicos de fenoximetilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13150322.9T Active ES2554788T3 (es) 2009-05-07 2009-12-18 Compuestos Heterocíclicos de Fenoximetilo

Country Status (33)

Country Link
US (3) US8343973B2 (es)
EP (3) EP2427454B1 (es)
JP (2) JP5628902B2 (es)
KR (1) KR101662699B1 (es)
CN (2) CN102459242B (es)
AU (1) AU2009345802B2 (es)
BR (1) BRPI0924617A8 (es)
CA (1) CA2761032A1 (es)
CL (1) CL2011002792A1 (es)
CO (1) CO6460744A2 (es)
CR (1) CR20110648A (es)
DK (2) DK2427454T3 (es)
EC (1) ECSP11011479A (es)
ES (2) ES2554788T3 (es)
HK (2) HK1167402A1 (es)
HR (2) HRP20130482T1 (es)
HU (1) HUE026238T2 (es)
IL (2) IL216149A (es)
ME (1) ME02375B (es)
MX (1) MX2011011755A (es)
MY (1) MY183910A (es)
NZ (1) NZ596753A (es)
PE (1) PE20120900A1 (es)
PH (1) PH12013501321A1 (es)
PL (2) PL2427454T3 (es)
PT (2) PT2427454E (es)
RS (2) RS52838B (es)
RU (1) RU2531274C2 (es)
SG (1) SG175900A1 (es)
SI (2) SI2617420T1 (es)
SM (2) SMT201300070B (es)
WO (1) WO2010128995A1 (es)
ZA (1) ZA201108920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000175A (es) 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
AU2009345802B2 (en) 2009-05-07 2016-05-26 Forum Pharmaceuticals Inc. Phenoxymethyl heterocyclic compounds
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ10(pde10a)阻害剤としての置換6,7−ジアルコキシ−3−イソキノリノール誘導体
CA2874953A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200167B1 (pl) * 1999-11-05 2008-12-31 Sod Conseils Rech Applic Związki heterocykliczne o aktywności hamowania kalpain i/lub pułapkowania ROS, ich zastosowanie i kompozycje farmaceutyczne je zawierające oraz związki pośrednie
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
AU2003244080A1 (en) 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
AP2362A (en) * 2005-01-07 2012-02-08 Pfizer Prod Inc Heteroaromatic quinoline compounds and their use as PDE10 inhibitors.
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
MX2011000175A (es) * 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
AU2009345802B2 (en) 2009-05-07 2016-05-26 Forum Pharmaceuticals Inc. Phenoxymethyl heterocyclic compounds
RU2012112151A (ru) * 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
CA2807419C (en) * 2010-08-18 2019-09-24 Sunil Kumar Kc Diketones and hydroxyketones as catenin signaling pathway activators

Also Published As

Publication number Publication date
JP2015038112A (ja) 2015-02-26
RU2531274C2 (ru) 2014-10-20
CR20110648A (es) 2012-03-28
PH12013501321B1 (en) 2014-08-27
US20150322069A1 (en) 2015-11-12
IL216149A0 (en) 2012-01-31
PE20120900A1 (es) 2012-08-14
HRP20130482T1 (en) 2013-08-31
SMT201300070B (it) 2013-09-06
SMT201600031B (it) 2016-02-25
MX2011011755A (es) 2012-03-16
EP2427454B1 (en) 2013-03-20
ES2554788T3 (es) 2015-12-23
CN102459242A (zh) 2012-05-16
CO6460744A2 (es) 2012-06-15
ECSP11011479A (es) 2011-12-30
BRPI0924617A8 (pt) 2017-10-03
JP2012526107A (ja) 2012-10-25
AU2009345802B2 (en) 2016-05-26
EP2427454A1 (en) 2012-03-14
SI2427454T1 (sl) 2013-08-30
SG175900A1 (en) 2011-12-29
DK2617420T3 (da) 2015-12-07
RU2011149637A (ru) 2013-06-20
CL2011002792A1 (es) 2012-06-01
NZ596753A (en) 2013-09-27
BRPI0924617A2 (es) 2017-07-11
ME02375B (me) 2016-06-20
RS52838B (en) 2013-10-31
CN105125547A (zh) 2015-12-09
EP3020716A1 (en) 2016-05-18
AU2009345802A1 (en) 2011-12-15
PH12013501321A1 (en) 2014-08-27
HK1186981A1 (en) 2014-03-28
IL244059A0 (en) 2016-04-21
HRP20151273T1 (hr) 2016-01-29
RS54529B1 (en) 2016-06-30
HK1167402A1 (en) 2012-11-30
PL2617420T3 (pl) 2016-04-29
HUE026238T2 (en) 2016-06-28
US8946222B2 (en) 2015-02-03
JP5628902B2 (ja) 2014-11-19
IL216149A (en) 2016-02-29
US8343973B2 (en) 2013-01-01
EP2617420B1 (en) 2015-09-23
JP5943053B2 (ja) 2016-06-29
KR20120027268A (ko) 2012-03-21
CN102459242B (zh) 2015-08-26
ZA201108920B (en) 2012-08-29
MY183910A (en) 2021-03-17
DK2427454T3 (da) 2013-06-17
PT2427454E (pt) 2013-06-20
SI2617420T1 (sl) 2016-02-29
US20100292238A1 (en) 2010-11-18
CA2761032A1 (en) 2010-11-11
PT2617420E (pt) 2015-12-18
US20130143888A1 (en) 2013-06-06
EP2617420A1 (en) 2013-07-24
KR101662699B1 (ko) 2016-10-05
PL2427454T3 (pl) 2013-09-30
WO2010128995A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
ES2409404T3 (es) Compuestos heterocíclicos de fenoximetilo
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR061969A1 (es) Derivados halogenados de imidazo-piridino, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes anti vhc
AR060590A1 (es) Compuestos imidazo
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas
BR112014006840A2 (pt) derivados de pirrolopirimidina e purina
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR060591A1 (es) Compuestos imidazo
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR056888A1 (es) Derivados de heterociclil imidazol
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
CO6300864A2 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
MX2012015120A (es) Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica.
AR088235A1 (es) Derivados de pirazoloquinolina
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR066583A1 (es) Derivados de 3,3-espiroindolinona
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
AR087771A1 (es) Moduladores de la pde10
AR088474A1 (es) Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa